Navigation Links
Resverlogix Notice of Conference Call & Webcast
Date:8/21/2008

TSX Exchange Symbol: RVX

CALGARY, Aug. 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it will host a live teleconference on August 25, 2008 at 11:00 am MDT to provide a corporate update of the Company. Following the presentation there will be a live question and answer session.

The webcast can be accessed at the following link:

http://services.choruscall.com/links/resverlogix080825.html

Participants can also dial in for the conference call:

Dial information is as follows:

North American Toll Free Dial In: 1-800-319-4610

International Dial In: +1-604-638-5340

The webcast will be available on the Resverlogix website for replay for a period of 10 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jan Gray Joins Resverlogix Board of Directors
2. Resverlogixs Lead Drug Featured in Key Scientific Publication
3. Industry Leaders Select Resverlogixs RVX-208
4. /C O R R E C T I O N from Source -- Resverlogix Corp./
5. Resverlogix Notice of Conference Call & Webcast
6. Resverlogix Share Option Extension
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
9. Resverlogix is Presenting at IAS HDL Workshop
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... -- GenVec, Inc. (NASDAQ: GNVC ) today announced the ... board of directors effective on October 24, 2014.   Dr. Horovitz ... its chairman from June 2006 to November 2013.  During his ... and Audit Committees of the board.  "We ... service to GenVec, and its stockholders," said Wayne T. ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Latin ... the market in Latin America with analysis and forecast ... in 2013, and is expected to reach $2,366.8 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report defines ... analysis and forecast of revenue. This market is estimated ... million by 2019, at a Compound Annual Growth Rate ... through the TOC of the Asia-Pacific Speech Analytics market ... provided. It also provides a glimpse of the segmentation ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... in Diversity, Military and Campus Recruitment, and Employment Branding joins Pierpoint ... ... San Jose, CA (PRWEB) October 20, 2008 -- Pierpoint ... Vice President of Recruitment Operations and Diversity. Mr. Cantu, most recently ...
... SETAUKET, N.Y., Oct. 20 John S. Kovach,M.D., ... Biotechnology Holdings,Inc. (OTC Bulletin Board: LIXT), announces the ... of Directors., Dr. Sorensen is currently Board ... He is a highly experienced leader and,administrator in ...
... announced today that the Company will host an investor ... PM Eastern Time to present an,analysis of the data ... IT-R-006) for the treatment of nasolabial folds, or,wrinkles. On ... results from these two studies, which met all primary ...
Cached Biology Technology:Robert Cantu Appointed Vice President of Pierpoint International 2Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 2Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 3Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 4Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies 2
(Date:10/17/2014)... Accurate knowledge regarding Ebola is critical and pertinent for ... hazardous global outbreak and epidemic. The Journal, Disaster ... special issue, Ebola Virus and Public Health, to surround ... in this critical societal moment. , On October ... for Clinicians . The primer was prepared by Dr. ...
(Date:10/17/2014)... is available in German . ... very few drugs. When treating overdoses, doctors are often limited ... difficult if there is a combination of drugs involved. So ... accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from ... find an answer to this question. "The task was to ...
(Date:10/16/2014)... land managers have a new synthesis of recent research ... (MMC) forests in the two states. , The ... Oregon and Washington: A Synthesis of the Relevant Biophysical ... technical report published by the U.S. Forest Service,s Pacific ... request from managers for a synthesis of the large ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2
... The National Space Biomedical Research Institute (NSBRI) has renewed awards ... the Massachusetts Institute of Technology and Texas A&M University. In ... to work toward a Ph.D. that focuses specifically on space ... million over a five-year period. "MIT and Texas ...
... University of Illinois at Chicago has been awarded a ... community-based health promotion programs for older adults with osteoarthritis. ... on Aging. The study will compare Fit and ... program, with Fit and Strong! Plus, the traditional program ...
... Clemson University researchers are teaming up with Coastal ... of sensors along the Savannah River to gather data ... will collect and transmit real-time information about the quality ... Intelligent River project leaders Gene Eidson, director of Clemson,s ...
Cached Biology News:NSBRI renews space life sciences graduate programs at MIT, Texas A&M 2UIC study examines exercise and weight loss for older adults with osteoarthritis 2UIC study examines exercise and weight loss for older adults with osteoarthritis 3Clemson, Coastal Carolina universities to set hundreds of sensors in Savannah River 2
... CL3 series is designed to enhance ... clinical applications at a reasonable cost. ... quick connect rotors and various biocontainment ... interface allows you to control and ...
PP2B-Abeta (C-20)...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... a fully licensed, high throughput, water bath thermal ... to 24 microplates. This equates to 9,216 reactions ... A robotic arm rapidly transfers a basket of ... ramping times that are considerably faster than those ...
Biology Products: